News
IPSC
2.320
+0.87%
0.020
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Benzinga · 1d ago
Weekly Report: what happened at IPSC last week (0615-0619)?
Weekly Report · 6d ago
Century Therapeutics cuts CSO Chad Cowan salary to $296,150 under amended employment agreement
PUBT · 06/16 20:08
Weekly Report: what happened at IPSC last week (0608-0612)?
Weekly Report · 06/15 09:17
Century Therapeutics Shareholders Approve Directors and Share Increase
TipRanks · 06/12 21:03
Century Therapeutics (IPSC) Receives a Buy from Mizuho Securities
TipRanks · 06/10 00:45
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), SOPHiA GENETICS (SOPH) and Century Therapeutics (IPSC)
TipRanks · 06/09 16:40
Piper Sandler Reaffirms Their Buy Rating on Century Therapeutics (IPSC)
TipRanks · 06/09 11:18
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha · 06/09 09:18
Century Therapeutics presents new preclinical data for CNTY-813
TipRanks · 06/08 20:40
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy
TipRanks · 06/08 20:34
Century Therapeutics releases ADA 2026 preclinical presentation on CNTY-813 iPSC-derived islet therapy
PUBT · 06/08 20:11
Century Therapeutics Announces Presentation Of New Preclinical Data At American Diabetes Association Sessions Supporting CNTY-813 Novel Islet Cell Replacement Treatment
Benzinga · 06/08 20:10
Century Therapeutics targets CNTY-813 type 1 diabetes IND filing in Q4 2026
PUBT · 06/08 20:06
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Barchart · 06/08 15:05
These healthcare stocks have maintained Strong Buy ratings for months
Seeking Alpha · 06/08 14:59
Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 06/08 12:04
Weekly Report: what happened at IPSC last week (0601-0605)?
Weekly Report · 06/08 09:16
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Veeva Systems (VEEV) and CytomX Therapeutics (CTMX)
TipRanks · 06/04 13:11
CENTURY THERAPEUTICS INC <IPSC.O>: MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8
Reuters · 06/04 10:46
More
Webull provides a variety of real-time IPSC stock news. You can receive the latest news about Century Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.